1 / 5

Mycoplasma Testing Market

Mycoplasma Testing Market<br>

swati15
Télécharger la présentation

Mycoplasma Testing Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mycoplasma Mycoplasma Testing Market To Testing Market To Reach USD 1.42 Reach USD 1.42 Billion By 2026 Billion By 2026

  2. Market Market Summary Summary According to the current analysis of Reports and Data, the global Mycoplasma Testing market was valued at USD 541.2 million in 2018 and is expected to reach USD 1.42 million by year 2026, at a CAGR of 12.6%. Mycoplasma is the smallest discovered species of bacteria, mostly developed through the de-generative evolution from Gram-positive bacteria. Mycoplasma bacterial cell lacks a cell wall and can either be parasitic or saprotrophic. Though, there are around 200 different types of mycoplasma bacteria, most of them are harmless. Only 5 out of 200 cause severe infections in humans, which include Mycoplasma pneumonia, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum. Different species of mycoplasma cause different diseases in the human body. For example, Mycoplasma pneumonia affects the throat and lungs, while Mycoplasma genitalium is associated with urethra infection. Mycoplasma testing is used to diagnose present or past mycoplasma infection in patients. Mycoplasma microbes can exist as healthy flora in the patient’s throat, genitourinary tract, or respiratory tract. Additionally, due to the lack of cell wall, the mycoplasma bacterial cells are immune to a several common antibiotics. Furthermore, mycoplasma testing plays an essential role in cell culture and must be done at every step of product development, including cell banks, viral seed stocks, and final products. Read More: https://www.reportsanddata.com/report-detail/mycoplasma-testing-market

  3. Market Market Summary Summary Further key findings from the report suggest • Mycoplasma testing market is growing at a CAGR of 13.0% in Asia Pacific, followed by North America and Europe, with 12.8 % and 12.5% CAGR respectively. Increasing government support, coupled with high investments in R&D, is a major factor driving the market growth. • As of 2018, Kits & Reagents segment is the dominating Mycoplasma testing, which holds 47.5% of the global market. The Asia Pacific regional market is the chief revenue generating source for this product segment, followed by the North American and European regions. • As mycoplasma infection can become chronic, it reduces the efficiency and strength of the immune system, making it weak over time and highly increasing the risk of infections caused by other microorganisms. • Mycoplasma contamination is the most common but serious problem faced while culturing cells, thus proper mycoplasma testing should be carried out before production of the final product. For instance, the MycoProbe Mycoplasma Detection Kit can be used for high-throughput and routine screening of cell culture for detection of mycoplasma contamination. • Key participants include Thermo Fisher Scientific Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Norgen Biotek Corp. (Canada), GenBio (Canada), Meridian Bioscience, Inc. (U.S.), and SavyonDiagnostics (Israel).

  4. Market Market Summary Summary For the purpose of this report, Reports and Data has segmented the mycoplasma testing market on the basis of product type, technology type, application type, end use, and region: • Product Type (Revenue, USD Million; 2016–2026) Instruments Kits & Reagents • • • Application Type (Revenue, USD Million; 2016–2026) Cell Line Testing Virus Testing End of Production Cells Testing Others • • • • • End Use (Revenue, USD Million; 2016–2026) Pharmaceutical Companies Cell Banks Others • • • •

  5. About US About US Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact US Contact US John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

More Related